The companies said this week that the over-the-counter product, a generic equivalent to Reckitt Benckiser’s Mucinex ER tablets (guaifenesin 1,200 mg), is packaged and marketed as store brands or retailer own-label brands.
“This product approval and launch demonstrates the power of matching Perrigo’s OTC platform with Allergan’s world-class generics R&D capabilities,” stated Perrigo chairman and chief executive officer Joseph Papa. “Our teams together worked to bring this important product to our consumers and customers around the world. The Mucinex family of products is an important offering to our customers, and we look forward to launching the remaining products throughout 2016.”
Guaifenesin 1,200mg ER tablets are indicated to relieve chest congestion and break up mucus, making coughs more productive. The medicine totaled sales of about $71 million through food, drug and mass retailers during that last 12 months, Perrigo and Allergan reported.
In January, Allergan and Perrigo launched combination guaifenesin 600-mg and pseudoephedrine HCl 60-mg ER tablets, a store-brand alternative to RB’s Mucinex D expectorant and nasal decongestant product.
“Today’s launch of [store-brand] Mucinex 1,200-mg extended-release product underscores the power of bringing together two leading organizations in generic product development and OTC and store-brand products to deliver high-quality, affordable medicines for patients around the world,” commented Robert Stewart, executive vice president and president of generics and global operations at Allergan. “Perrigo has been an outstanding partner in bringing this and other Mucinex store-brand products to market, and we look forward to our continued efforts to bring additional formulations of the Mucinex family of products forward for the patients and customers that we serve.”